Trial · NCT01145417
Results by group170
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 170
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin-Pregabalin | AEs | 67 | participants | |
| Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo-Pregabalin | AEs | 70 | participants | |
| Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin-Pregabalin | SAEs | 4 | participants | |
| Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo-Pregabalin | SAEs | 3 | participants | |
| Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Pregabalin-Pregabalin | Baseline, employed (n=52,51) | 12 | participants | |
| Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Placebo-Pregabalin | Baseline, employed (n=52,51) | 11 | participants | |
| Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Pregabalin-Pregabalin | Baseline, unemployed (n=52,51) | 40 | participants | |
| Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Placebo-Pregabalin | Baseline, unemployed (n=52,51) | 40 | participants | |
| Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Pregabalin-Pregabalin | Week 24, employed (n=103,104) | 35 | participants | |
| Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Placebo-Pregabalin | Week 24, employed (n=103,104) | 27 | participants | |
| Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Pregabalin-Pregabalin | Week 24, unemployed (n=103,104) | 68 | participants | |
| Number of Participants Who Were Employed or Unemployed Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Placebo-Pregabalin | Week 24, unemployed (n=103,104) | 77 | participants | |
| Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Pregabalin-Pregabalin | Baseline, hours missed,leg/foot pain (n=12,11) | 2.25 | Standard Deviation 6.877 | hours |
| Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Placebo-Pregabalin | Baseline, hours missed,leg/foot pain (n=12,11) | 0.82 | Standard Deviation 2.401 | hours |
| Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Pregabalin-Pregabalin | Baseline, hours missed,other reason (n=12,11) | 3.42 | Standard Deviation 6.501 | hours |
| Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Placebo-Pregabalin | Baseline, hours missed,other reason (n=12,11) | 0.91 | Standard Deviation 1.700 | hours |
| Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Pregabalin-Pregabalin | Baseline, hours worked (n=12,11) | 35.58 | Standard Deviation 15.163 | hours |
| Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Placebo-Pregabalin | Baseline, hours worked (n=12,11) | 30.36 | Standard Deviation 18.112 | hours |
| Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Pregabalin-Pregabalin | Week 24, hours missed,leg/foot pain (n=35,28) | 2.17 | Standard Deviation 4.956 | hours |
| Absenteeism and Presenteeism Assessed by Work Productivity and Activity Impairment: Specific Health Problem (WPAI: SHP) Questionnaire | Placebo-Pregabalin | Week 24, hours missed,leg/foot pain (n=35,28) | 2.32 | Standard Deviation 8.533 | hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01145417/results